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Abstracts / Urological Science 27 (2016) S53eS83S54for sexual life impairment (p values, 3 months after radiotherapy and > 3
months after radiotherapy, 0.017 and 0.004, respectively). There were
some limitations in this study, including single-institute and outpatient
alone.
Conclusion: During the initial 5-year follow-up, both radical prostatec-
tomy and radiotherapy had one-to-two year negative impacts on global
QoL in localized patients. Both hormonal therapy and palliative radio-
therapy had one-to-two year positive impacts on global QoL in metastatic
patients. Radiotherapy had a profound long-term decrease in sexual life
performance. These results can help physicians and patients in decision
making for optimal therapy.
NDP004:
ANALYSIS OF DETRUSOR MUSCLE SAMPLING DURING TRANSURETHRAL
RESECTION OF BLADDER TUMOR IN NON-MUSCLE INVASIVE BLADDER
CANCER
Yuan-Cheng Chu, See-Tong Pang, Ying-Hsu Chang, Cheng-Keng Chuang,
Po-Hung Lin, Chung-Yi Liu. Division of Urology, Department of Surgery,
Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan
Purpose: Transurethral resection of bladder tumor (TUR-BT) plays an
important role in the treatment and diagnosis of non-muscle invasive
bladder cancer (NMIBC). However, the pathology report of the bladder
tumor often had no detrusor muscle presentation. In this situation, it is
difﬁcult to decided the advanced treatment. Therefore, we analysis that
the detrusor muscle presentation inﬂuence the prognosis and the factors
affect the detrusor muscle presentation.
Materials and Methods: Retrospective review the pathology report of
TUR-BT from 2013 Jan. to 2013 Dec. in Chang Gung Memorial hospital in
Linkou. All patients was follow up for at least one-year.
Results: There are 150 patients underwent TUR-BT at Linkou CGMH in this
year. The NMIBC cases was about 100 (66.7%). The pathology report
showed detrusor muscle was 37% and no mention of detrusor muscle was
5%. Compared between the detrusor muscle present and the detrusor
muscle absent, the mortality rate within 1 year (0% v.s. 3%, p¼ 0.157) and
early recurrent rate (14% v.s. 12%, p> 0.05) had no signiﬁcant difference.
Besides, larger bladder tumor (>3cm, p¼ 0.037) and high-grade bladder
tumor (p¼ 0.018) had higher detrusor muscle presentation rate. Therewas
no difference in age (p¼ 0.298), gender (p¼ 0.454) and primary stage
(p¼ 0.383) in detrusor muscle presentation rate.
Conclusion: In this data, there was no obvious difference of prognosis
within 1 year, but need longer time of follow up to prove that. Pathol-
ogists rightly mention detrusor muscle when there is a higher proba-
bility of invasion. This help the clinic physician for further treatment
decision.
NDP005:
SEMI-RIGID URETEROSCOPY WITH THULLIUM LASER FOR THE
TREATMENT OF URETER UROTHELIAL CARCINOMA: EXPERIENCE OF
MACKAY MEMORIAL HOSPITAL
Ting-Po Lin. Department of Urology, Mackay Memorial Hospital, Taipei,
Taiwan
Purpose: Radical nephroureterectomy is the standard treatment of high
risk upper tract urothelial carcinoma (UTUC). However, renal-sparing
treatment as endoscopic ablation or segmental resection can be used
for low risk ureter urothelial carcinoma without compromising onco-
logical outcomes. In present study, we share the experience of using
semi-rigid uretersoscope with Thullium laser to treat ureter urothelial
carcinoma.
Materials and Methods: We retrospectively reviewed 9 cases with ureter
urothelial carcinoma managed by Thullium laser with semi-rigid ureter-
soscope from January 2014 to June 2015 in our hospital. Peri-operative
outcome and post-operative outcome were recorded.
Results: There are 9 patients underwent endoscopic treatment. Mean
(range) age was 67.1 (56~85) years old. Mean (range) follow up was 13.9
(3~22) months. Overall survival rate was 100%. Five patients received
endoscopic management due to low-risk tumor. Upper tract progression
or persisted carcinoma in situ was noted in three patients (60%), all ofthem received nephroureterectomy after then. Four patients received
endoscopic treatment because they are not suitable to nephroureter-
ectomy. All of the four patients with high risk or not suitable to neph-
roureterectomy had recurrence. No major complication was noted
perioperatively.
Conclusion: After endoscopic surgery, upper tract recurrence is common
even in low risk tumor. Regular surveillance with URS is needed. Salvage
nephroureterectomy is advised during close follow up.
NDP006:
COMPLEMENTARY TRADITIONAL CHINESE MEDICINE THERAPY
IMPROVES SURVIVAL IN PATIENTS WITH METASTATIC PROSTATE
CANCER
Jui-Ming Liu 1, Po-Hung Lin 2, Shun-Ku Lin 3, Ren-Jun Hsu 4. 1Division of
Urology, Department of Surgery Taoyuan General Hospital, Ministry of
Health and Welfare, Taiwan; 2Department of Urology, Chang Gung
Memorial Hospital, Taiwan; 3Department of Chinese medicine, Taipei City
Hospital, Ren-Ai Branch, Taiwan; 4Department of Pathology and Graduate
Institute of Pathology and Parasitology, the Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan
Purpose: More than 50% of prostate cancer patients have used traditional
Chinese medicine (TCM) in Taiwan. However, the long-term clinical efﬁ-
cacy of TCM in prostate cancer patients remains unclear. Here, we inves-
tigated the relationship between TCM use and the survival of prostate
cancer patients.
Materials and Methods: A retrospective nationwide cohort study of
prostate cancer patients was conducted between 1998 and 2003 using the
Taiwan National Health Insurance Research Database. The association
between death risk and TCM use was determined using Cox proportional
hazards models and Kaplan-Meier curves.
Results: Of the 1132 selected prostate cancer patients, 730 (64.5%) and 402
(35.5%) were TCM users and non-usrs, respectively. The mean follow-up
period was 8.38 years, and 292 (25.8%) deaths were reported. TCM users
had a decreased mortality rate (21.9%) compared to non-users (32.8%). A
lower death risk was observed with longer TCM use, especially in patients
who used TCM for S200 days (aHR, 0.61; 95% CI, 0.44e0.84). TCM users
with metastatic prostate cancer had a signiﬁcant lower hazard ratio than
non-users (aHR, 0.70; 95% CI, 0.51e0.95).
Conclusion: The result suggested that TCM might be associated with a
reduced risk of death in metastatic prostate cancer patients
NDP007:
UPPER URINARY TRACT TRANSITIONAL CANCER-THE EXPERIENCES IN
RECENT 5 YEARS AND LITERATURE REVIEW
Kuan-Tang Huang, Mao-sheng Lin. Department of Urology, Show-Chwan
Memorial Hospital, Changhua, Taiwan
Purpose: It has been shown that there are some difference of the distri-
bution of the upper urinary tract cancer between Taiwanese and other
races. Previous studies have shown an increased risk of upper urinary tract
urothelial carcinoma. We try to re-examine this risk.
Materials and Methods: We enrolled all 93 patients of upper urinary tract
cancer in Show-Chaun hospital in Chang-Hua Taiwan during 2008e2015,
and we retrospectively followed the development of cancer until 2012 by
analysis of data collected from the Taiwan Cancer Registry.
Results: There were 93 newly diagnosed cases of upper urological cancer
and most of them were transitional cell carcinoma (70.1%) and renal cell
carcinoma (28.0%). The mean age at diagnosis for upper urinary tract
cancer was 65.5 years. Focusing on urothelial carcinoma, when stratiﬁed
by location, there are 45.2% in renal pelvis, 32.6% in upper ureter and 20.4%
in both. About the tumor stage, there are 28.3% patients was stage I, 19.8%
was stage II, 35.0% was stage III and 16.9% was stage IV. The crude death
rate during 2008 to 2015 was 9.31% in stage I, 7.23% in stage II, 30.4% in
stage III and 66.7% in stage IV, respectively.
Conclusion: The urothelial carcinoma consisted the majority of upper
urinary tract cancer in Taiwan, followed by renal cell carcinoma. Most of
the urothelial carcinoma was located in the renal pelvis. It makes the
diagnosis more challengeable.
